News Releases

Aug 13, 2026

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Aug 03, 2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 03, 2026

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Jul 29, 2026

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

Jul 08, 2026

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 01, 2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2026

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Jun 25, 2026

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Jun 02, 2026

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Jun 01, 2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)